کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6182870 | 1254037 | 2014 | 7 صفحه PDF | دانلود رایگان |
- Endometriosis associated tumors had an increase in synchronous endometrial cancer.
- Cases had an improved 5Â year disease free survival vs. papillary serous controls.
- There was no difference in 5Â year overall survival between cases and controls.
ObjectiveThe aim of this investigation was to compare outcomes of patients with clear cell carcinoma (CCC) and endometrioid carcinoma (EC) of the ovary associated with endometriosis to patients with ovarian papillary serous carcinoma (PSC).MethodsPatients with CCC and EC of the ovary associated with endometriosis were identified and matched by age and stage to PSC controls. Student's t test and chi square test were used to analyze continuous and categorical data. The Kaplan-Meier method was used for survival analysis.Results67 cases associated with endometriosis were identified, of which 45 were arising in endometriosis. Cases were matched to 134 PSC controls. 27 patients with tumors associated with endometriosis presented at stage I (40.3%), 27 at stage II (40.3%), ten at stage III (14.9%) and three at stage IV (4.5%). There was no difference in rate of optimal cytoreduction or response to chemotherapy in cases vs. PSC controls. There was a significant increase in synchronous endometrial cancer in tumors associated with endometriosis compared to PSC (25.4% vs. 3.7%; PÂ <Â 0.001). 18 cases (26.9%) had recurrent disease vs. 55 (41%) controls (PÂ =Â 0.03). The 5-year disease-free survival (DFS) and overall survival (OS) of patients with tumors associated with endometriosis compared to PSC controls were 75% vs. 55% (PÂ =Â 0.03) and 85% vs. 77% (PÂ =Â 0.2), respectively.ConclusionsPatients with tumors associated with endometriosis had a higher rate of synchronous endometrial cancer. Cases also demonstrated a lower rate of recurrence and improved 5Â year DFS; however, this did not translate into a difference in OS.
Journal: Gynecologic Oncology - Volume 132, Issue 3, March 2014, Pages 760-766